Navigation Links
New Biotech Drugs to Aid in Renal Cell Carcinoma Treatment

Two biotech drugs produced by Bayer AG, Pfizer and Onyx pharmaceuticals are astounding doctors with their effects on decreasing the progression// of metastatic kidney cancer.

The drugs, sunitinib (marketed under brand name Sutent) and sorafenib (brand name Nexavar) have been found to delay the progression of renal cell carcinoma by 3 to 6 months.

Renal cell carcinoma is the most common of all kidney cancers; 90 percent of kidney cancers diagnosed in the US are due to this cancer. It is responsible for 1.5 percent of all cancer deaths and around 30,000 cases of renal cell carcinoma are diagnosed every year.

The standard drugs used are interferon alfa and interleukin-2. Yet these drugs help in only 5 percent of cases where the tumors have spread. Hence the excitement over the new drugs.

Researchers from US, France and Poland, contributed to the results of the study published in the New England Journal of Medicine.

The studies report how sunitinib when given to patients slowed the progression of the disease or development of tumors, to 11 months as against 5 months with interferon alfa. This was tested on 375 cancer patients.

In the case of sorafenib, half of 903 volunteers from 19 countries were put on the drug, while the other half received a placebo. Those who took the drug showed an extra period of around 3 months in delay of tumor growth.

The results were so effective that doctors are now thinking of placing the control patients on the drug.

Yet side effects of the drugs persist and can be severe in some patients. They include skin rashes, diarrhea and increased blood pressure.

Both drugs work by inhibiting the blood flowing to the tumor and hence limiting its growth.

"Kidney cancer has always been regarded as a cancer in which there was no progress," explains the lead author of the sunitinib study, Dr. Robert Motzer from Memorial Sloan-Kettering Cancer Center in Ne w York City. "Based on a better understanding of tumor biology, this new medication (sunitinib) was developed, and it has remarkable activity that has resulted in a complete change in the way we treat this cancer."

Dr. James Brugarolas from the University of Texas Southwestern Medical Center, another researcher, adds,” The two new drugs represent a major step forward in our fight against kidney cancer that was made possible by obtaining a greater understanding of the molecular genetics and biology of the disease. These drugs are clearly effective against the tumor.”
AN
'"/>




Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Vical Biotech and NIH jointly develops HIV vaccine
9. Biotechnology Initiatives Planned In Hyderabad
10. Biotech Osiris to go public
11. Western Region Tops in Indian Biotech Growth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future ... , As Winston Churchill said, “Those who don’t learn from history are doomed ... to expect when they come knocking this year. But that takes time. , Take ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a ... initiating a charity drive that will raise funds earmarked to purchase computers and software ... Elementary School. , “My school is in a low-income area and has more than ...
(Date:2/12/2016)... ... 2016 , ... Donor Network West, the organ procurement organization that heals lives ... San Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific ... a more certain time frame for donor families for the recovery of organs. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and SEOUL, South Korea , ... and Macrogen, Inc. today announced they will form ... procedures for precision medicine in cancer. The goal ... DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next Generation ... under the Clinical Laboratory Improvement Amendments (CLIA) of ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/11/2016)... 11, 2016 - Cardiac ... Personalized Medicine and Cancer Therapy. - European Point ... Testing Markets. - Key Diagnostic Testing Markets. ... Diagnostics in Genetic Testing. - Molecular Diagnostics in ... - Over-the-Counter Diagnostic Products World Markets. - Point ...
Breaking Medicine Technology: